A prescription travels from the doctor who writes it, to the pharmacist who dispenses it, with a field representative connecting both. MedShorts gives all three the same accurate, bite-sized science, through one personalised link they can open on any phone.
One new story for each specialty, every morning: short, sourced and readable between patients.
None of today's stories are in your chosen specialties. Change specialties or browse all of MedShorts 360.
CardiologyIn a 10-patient phase 1b study presented at AHA 2026, a single infusion of the gene-editing therapy CTX310 lowered median triglycerides by about 63% at 30 days, with no serious treatment-related adverse events.
DiabetologyIn a US randomised trial of more than 150 adults with prediabetes, a month of real versus sham bedroom air filtration cut fine particles by 36% and was linked to lower post-breakfast glucose peaks on continuous monitoring.
NephrologyIn 6,220 Australian adults followed for 12 years, each additional hour of daily TV viewing was associated with a 2–3% faster yearly fall in eGFR, with a stronger signal in people with type 2 diabetes.
NeurologyIn a 380-patient phase 3 trial in drug-resistant focal epilepsy, once-daily azetukalner 15 mg or 25 mg, started without titration, reduced monthly seizures more than placebo, with dizziness the main side effect.
UrologyIn a UK phase 2 trial analysis of 77 men with castration-resistant prostate cancer and up to two progressing metastases, those with detectable ctDNA before SBRT had median progression-free survival of 3.0 versus 7.8 months.
PsychiatryA network meta-analysis of 115 randomised trials with over 30,000 participants found escitalopram, agomelatine and duloxetine more effective than fluoxetine at keeping patients with major depression well over the long term.
PulmonologyIn a 48-week single-centre phase II study of 39 patients with RA-associated ILD, tofacitinib 5 mg twice daily modestly lowered serum KL-6, with an FVC change of -72 mL and 51% reaching low RA disease activity.
Critical CareA multinational study of nearly 29,000 ICU patients found that going without pharmacist medication management for at least one day raised the odds of in-hospital death by 20%, and higher pharmacist workloads also raised risk.
GastroenterologyThe FDA has approved bepirovirsen, added to existing antivirals, for adults with chronic hepatitis B without cirrhosis and low HBsAg; in two trials 19% kept the virus controlled 24 weeks after stopping all treatment.
DermatologyA Journal of Experimental Medicine study linked psoriasis to a Vanin enzyme pathway in dendritic cells; in a 24-patient pilot, adding oral pantethine to topical treatment gave greater improvement over 12 weeks.
OphthalmologyAn IRIS Registry study of 80,106 eyes with early or intermediate dry AMD found a modestly higher six-year conversion rate to neovascular AMD after cataract surgery, with the excess risk concentrated in the first years.
ENTThe FDA has approved subcutaneous amivantamab for recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and immunotherapy, based on a 42% response rate in a 102-patient trial.
OrthopaedicsIn 3,552 adults followed for about 5.7 years, hand synovitis on ultrasound was tied to a 26% higher adjusted risk of death, with stronger links when bilateral or affecting several joints.
GynaecologyA meta-analysis of 13 studies (4,057 women under 20 weeks) found emergency physician-performed ultrasound cut ED stay by about an hour without a significant rise in missed ectopic pregnancies.
PaediatricsIn a 166-family US trial, adolescents given emotion-regulation training alongside family-based behavioural treatment lost similar weight but regained less and ate less emotionally at 12-month follow-up.
SurgeryA Korean target trial emulation of 802 asymptomatic patients found early surgery associated with 31% lower all-cause mortality than watchful waiting over a mean of about seven years.
General MedicineA 12-year review at a Nagpur government STI clinic found 296 syphilis cases, most diagnosed in 2022–2024; latent syphilis made up 45.6%, and many patients were young men.
Add MedShorts to your phone's home screen: today's stories in one tap, full screen, no app store needed.
Indian pharma has traditionally put almost all of its scientific effort into one moment: the representative's few minutes with a doctor. Yet outcomes depend on much more than that moment. The pharmacist decides how a medicine is explained, substituted and taken. The representative's own confidence in the science shapes every conversation. And the doctor, seeing dozens of patients a day, needs updates that fit between consultations, not another hour-long webinar.
MedShorts began as a smart way to send doctors a personalised content library through a single link. We are now extending it into a broader strategic initiative: a knowledge network that serves the doctor, the pharmacist and the field force together, with consistent science, the right depth for each role, and one view of engagement for the brand team.
The result is fewer disconnected campaigns and more joined-up education, where the doctor's prescription, the pharmacist's counselling and the representative's message all say the same thing.
Each audience gets its own experience, written for how they work and what they need to decide, while the science underneath stays the same.
Short clinical updates, guideline summaries, journal digests and KOL perspectives, curated by specialty and delivered to the phone.
Practical capsules on dosing, interactions, storage, adherence and safety, written for community and hospital pharmacists.
Micro-learning on disease, molecule and evidence, with assessments, certification and approved links representatives can share with doctors.
When all three roles learn from the same source, the patient hears one consistent story about their treatment.
Learns the evidence, passes certification, shares an approved MedShorts link.
Reviews the update in minutes, prescribes with the latest guidance, shares patient material.
Dispenses correctly and counsels on dose, timing, side-effects and adherence.
Every piece is written from published evidence and guidelines, reviewed by our medical team and kept to the length a busy clinician will actually finish.
Personalised links by SMS, email and WhatsApp, QR codes at pharmacies and clinics, and representative-shared links. No app to download.
Quizzes, case challenges and certification turn content into measurable learning, with deeper courses on Medigene Learn.
Open, read-through, video-completion and quiz data by audience, specialty and region, reported in one dashboard.
Medical and regulatory review, content aligned with the approved prescribing information, consent-based contact and data handled under India's data-protection law.
Designed for low-bandwidth mobile use, with English and Hindi as standard and regional languages for pharmacist and patient material.
A personalised MedShorts link arrives by SMS, email or WhatsApp, or is shared by a representative.
One tap opens a secure, mobile-friendly library. A one-time registration keeps it personal.
Short articles, videos, infographics and quizzes, chosen for the reader's role and specialty.
Apply it in practice, share patient material, or continue to a full CME course.
Engagement flows into the brand dashboard and shapes the next content cycle.
Two-to-three-minute reads on a single clinical question.
Expert perspectives in three-to-five-minute clips.
Landmark and recent trials summarised with key numbers.
What changed, and what it means in clinic.
Test and reinforce, with instant explanations.
Leaflets and videos doctors and pharmacists can share.
Lung-sound and ECG trainers, calculators and checklists.
Interaction, storage and pharmacovigilance reminders.
MedShorts already hosts series in neurology, cardio-metabolic care, respiratory medicine, orthopaedics, oncology, women's health, critical care, dermatology, dentistry and ophthalmology, including interactive trainers for lung sounds and ECG interpretation.
The new network brings these together in one library and adds dedicated tracks for pharmacists and field teams.
Talk to us about a MedShorts programme that reaches your doctors, their pharmacists and your field force with one consistent, compliant message.